Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01498952 · ClinicalTrials.gov registry record · Phase 1
MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
A Phase 1 study of Unresectable or Metastatic Hepatocellular Carcinoma (HCC), sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 3
- Study locations
NCT01498952 is a Phase 1 study of Unresectable or Metastatic Hepatocellular Carcinoma (HCC) that has completed, run by MedImmune. The registered enrollment target is 6 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT01498952, a Phase 1 study of Unresectable or Metastatic Hepatocellular Carcinoma (HCC), has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 3
- Study locations
Study Summary
A Phase 1b/2, open-label, randomized study to evaluate MEDI-573 in combination with standard of care in adult subjects with unresectable or metastatic hepatocellular carcinoma (HCC).
Conditions Studied
Interventions
- DRUG Sorafenib
- DRUG MEDI-573 (1 of 3 doses)
Study Locations (3)
California
- Research Site - Oxnard
Colorado
- Research Site - Golden Springs
Nevada
- Research Site - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-01-17 |
| Est. Completion | 2013-04-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01498952
The ClinicalTrials.gov registry entry for NCT01498952 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unresectable or Metastatic Hepatocellular Carcinoma (HCC) appearing as the primary indexed condition, and to 2 interventions - of which Sorafenib is the first listed.
NCT01498952 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Colorado, Nevada.
Frequently Asked Questions
What is clinical trial NCT01498952 about?
NCT01498952 is a clinical study titled "MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.". A Phase 1b/2, open-label, randomized study to evaluate MEDI-573 in combination with standard of care in adult subjects with unresectable or metastatic hepatocellular carcinoma (HCC).
What is the current status of trial NCT01498952?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2012-01-17. Estimated completion is 2013-04-09.
What conditions does trial NCT01498952 study?
This clinical trial studies the following conditions: Unresectable or Metastatic Hepatocellular Carcinoma (HCC).
What interventions are being tested in trial NCT01498952?
The interventions under investigation include: Sorafenib (DRUG), MEDI-573 (1 of 3 doses) (DRUG).
Who is sponsoring clinical trial NCT01498952?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01498952 being conducted?
This trial has 3 study locations across California, Colorado, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.